![beem stock outlook beem stock outlook](https://thumbs.dreamstime.com/z/mountain-outlook-view-peaks-protruding-clouds-postcards-leaflets-labels-headers-vector-illustration-33600144.jpg)
![beem stock outlook beem stock outlook](http://agmmcdn.s3.amazonaws.com/agmmcdn/2013/09/Construction-industry-steel-aluminum-prices-US-housing-market-outlook-september-2013.gif)
The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. Beam Global is currently a Zacks Rank #3 (Hold). The Zacks Consensus EPS estimate has moved 9.17% lower within the past month. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Our research shows that these estimate changes are directly correlated with near-term stock prices. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. These revisions help to show the ever-changing nature of near-term business trends. Investors should also note any recent changes to analyst estimates for Beam Global. These totals would mark changes of +10.81% and +92.85%, respectively, from last year.
#Beem stock outlook full#
The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.66 per share and revenue of $17.36 million.
#Beem stock outlook license#
and collaboration and license agreement with Verve Therapeutics, Inc. It also has a research collaboration agreement with Pfizer Inc. and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. license agreement with Sana Biotechnology, Inc.
#Beem stock outlook trial#
The company has an alliance with Boston Children's Hospital a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc. It also develops therapies for alpha-1 antitrypsin deficiency ocular diseases and other liver, muscle, and central nervous system disorders. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia BEAM-102 for the treatment of sickle cell disease and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.